Eli Lilly's Q1 Earnings Surge on Strong Zepbound and Mounjaro Sales

The pharmaceutical giant raises full-year guidance as demand for weight-loss and diabetes drugs exceeds expectations.

Eli Lilly's stock soars, adding billions to its market value as first-quarter earnings beat estimates.
Zepbound and Mounjaro drive significant revenue growth, with sales reaching $517.4 million and $1.81 billion respectively.
The company raises 2024 revenue and earnings guidance due to high demand and plans to expand production.
Supply constraints persist, but significant increases in production are expected in the second half of the year.
Analysts remain bullish on Eli Lilly, projecting unprecedented growth over the next decade.